
Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute, discusses the successes and challenges of a population health reimbursement model and gives advice for other health organizations considering a similar partnership within their practices.

Afreen Idris Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, discusses how e-consults are addressing specific endocrine immune-related adverse events from immune checkpoint inhibitors (ICIs), reducing time to appointment, and lowering the need for hospitalization.

Patients with Medicare were 5.08 times more likely than patients with private insurance, and 2.81 times more likely than patients with Medicaid, to face a financial barrier to obtaining varenicline and combination nicotine replacement therapy.

Cigna will pay $172 million to resolve allegations that it submitted inaccurate diagnosis codes for Medicare Advantage plan enrollees in order to increase payments from Medicare.

A co-expression network analysis pinpoints different gene expressions that can potentially predict rheumatoid arthritis (RA) outcomes during pregnancy.

There are many immunotherapy-caused skin toxicities, but most can be easily managed.

Updated findings from a phase 1/2 trial of stem-cell derived islet cell therapy for type 1 diabetes (T1D) showed improved glycemic control and a reduction in insulin dependence.

Stronger associations were identified between comorbidities and severe asthma compared with patients without, a study finds.

Although children with sickle cell disease (SCD) frequently present with abdominal pain, limited gastrointestinal evaluations are performed for them.

Sexual and gender minority (SGM) patients with chronic inflammatory skin diseases (CSIDs) may be disproportionately influenced by cost and noncost obstacles to health care.

The rare disease Fanconi anemia is an inherited bone marrow disorder linked to birth defects that leads to failure of bone marrow, the spongy material inside the bones where stem cells develop.

Age-related macular degeneration (AMD) and impaired vision were found to be associated with choriocapillaris flow signal deficits in patients 60 years and older.

Rajini Katipamula-Malisetti, MD, executive vice president of Minnesota Oncology, defined value-based cancer care and its importance.

Successfully increasing colorectal cancer screening rates in African Americans could be achieved through the key roles of in-person interactions and community contexts.

The data show the average age of dialysis in the least vulnerable neighborhoods was 68.2 years old, but 59.4 years—almost a decade earlier—in the most vulnerable.

The interrelated concepts of burnout, secondary traumatic stress, moral distress, compassion fatigue, and compassion satisfaction have been identified as having a profound impact on the quality of life of health care providers.

Providers have to know how to manage patients who are hesitant to switch to a biosimilar and payers who have specific preferences about which biosimilar to use.

Clostridioides difficile (C difficile) screening in all ICU admissions identified asymptomatic carriers and their risk for developing and/or transmitting infection.

FDA is investigating fraudulent schemes trafficking counterfeit semaglutide (Ozempic); Moderna plans to begin a late-stage trial of its combined COVID-19 and flu vaccine later this year; CMS will begin restricting predictive software used by insurance companies next year.

A presentation at the Association of Community Cancer Centers’ 40th National Oncology Conference explored how a cancer screening initiative can be sustainable and revenue positive while driving value-based savings in an evolving market.

Margaret Liang, MD, MSHPM, gynecologic oncologist and program director for the gynecologic oncology fellowship program at Cedars-Sinai Cancer Center, discusses the Association of Community Cancer Centers' Financial Advocacy Services guidelines, which focus on providing financial support to patients with cancer.

A recent study suggests that a patient’s immune microenvironment plays a key role in the depth and duration of response to multiple myeloma treatment.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, speaks on the unique perspectives and challenges smaller health care practices may face when entering into alternative payment models and shares key insights for addressing these issues.

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.

These findings support the importance of children with atopic dermatitis (AD) receiving patch testing to consider allergic contact dermatitis as a comorbidity.

A poster presented at the 40th National Oncology Conference addressed several hot topics in the oncology treatment and research space: addressing medical mistrust in underresourced communities, partnering with trusted organizations to improve health equity, and increasing inclusivity in research.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
